News

Evidence for assessing the efficacy and safety of anti-vascular endothelial growth factor (VEGF) agents for treating corneal and ocular surface disease is accumulating. However, there is clearly a need for more research to define if, when, and how this therapy should be used, said Anat Galor, MD.

A targeted approach to treatment based on the findings of a thorough history, appropriate testing, and clinical exam can be successful for bringing relief to many patients with dry eye that is difficult to manage, said Deepinder K. Dhaliwal, MD.

Heidelberg Engineering GmbH announces an ophthalmic picture archiving and communication system (PACS) platform.

As more state legislatures are relaxing anti-marijuana laws, doctors are being put in the middle by patients requesting prescriptions or authorizations for its use for medical needs, said Marc F. Lieberman, MD.

OCULUS Surgical launched ImproVue ophthalmic lubricant drops for topical use to hydrate and lubricate the outer surface of the eye.

There has been considerable progress in treatment for diabetic macular edema (DME) in the last several years, but a look at the investigational pipeline indicates further advances are likely on the horizon, said Peter A. Campochiaro, MD.

It is with great excitement that we unveil our network-wide redesign. Please read further to learn more about a few of our new features, and browse around to explore the new site!

Although the prognosis for posterior uveal melanoma remains poor, a look at recent developments and ongoing research provides hope for better outcomes in the future, said Jerry A. Shields, MD, in his delivery of the 2014 Charles L. Schepens, MD, Lecture.

Results from 1 year of follow-up show that transepithelial corneal crosslinking (CXL) with iontophoresis appears to be safe and effective in arresting the progression of keratoconus, said Paolo Vinciguerra, MD.

Abbott and Carl Zeiss Meditec announced that they have entered into a non-exclusive commercial collaboration in the United States.

There are already several good reasons for ophthalmic surgeons to perform “heads-up” surgery. Further benefits to support its use are anticipated as the technology continues to evolve, said Claus Eckardt, MD, professor of ophthalmology, Klinikum Frankfurt Höchst, Frankfurt, Germany.

Preliminary results from the Patient Reported Outcomes with LASIK-1 (PROWL-1) and PROWL-2 studies show that at 3 months after surgery, more than 95% of patients are seeing 20/20 or better uncorrected binocularly and more than 90% have monocular uncorrected visual acuity of 20/20 or better, said Malvina B. Eydelman, MD.

A novel medical device from BlephEx allows physicians to perform a painless, in-office procedure to treat blepharitis-thus relieving patients from the chronic and irritating symptoms of inflammatory lid disease and dry eye.

Two zombies are eating a comedian. First zombie says to the second one: “do you taste something funny?”

A recent national public opinion poll reflects racial and ethnic populations and their attitudes about vision and vision loss.

The management of orbital vascular lesions in the endovascular operating room appears to be safe and well controlled with real-time surveillance to facilitate the surgical resection.

The development of a device for 24-hour IOP monitoring is unique in that it can do so autonomously, without direct patient interaction, and can take measurements without external control signals.

The development of sustained, ocular drug delivery aims to remove patient compliance in order to achieve the therapeutic effect.

A small study of donor corneal tissues has shown that positive sputum cultures prior to death are not correlated with positive graft cultures after preparation. Despite the presence of low levels of various pathogens, no growth was found in any bacteria or fungus rim cul-tures.

ONO-9054, a drug being developed for the treatment of ocular hypertension and primary open angle glaucoma, showed promising results in a small, randomized trial. Post-hoc analysis of the results showed that nearly 90% of patents who had received doses of 10 µg/mL or higher had IOP measurements of 18 mm Hg or lower following treatment.

A stitch-less blepharoplasty procedure is possible with use of a new topical skin adhesive.

Examining the pros and cons of maintaining or starting an optical dispensary within an ophthalmic practice.

Alcon recently announced a partnership to in-license Google’s smart lens technology, but many questions remain. What will this new product bring to eye care and will it change ocular medicine?

A new presbyopia-correcting IOL has a novel optic combining two complementary diffractive technologies. Results from bench and clinical testing show it provides a full range of continuous, high-quality vision, minimizes dysphotopsias, and may be more tolerant to refractive errors than multifocal IOLs.

Outcomes of an initial pilot study conducted in a preclinical animal model support further research investigating tumor necrosis factor-? stimulated gene/protein-6 (TSG-6) as a novel treatment for chemical injury to the cornea, said Samuel F A Fulcher, MD.

The FDA has approved VisionCare Ophthalmic Technologies’ Implantable Miniature Telescope (by Dr. Isaac Lipshitz) for use in patients living with bilateral end-stage age-related macular degeneration (AMD) who are age 65 or older.

Health Canada has approved Novartis Pharmaceuticals Canada’s ranibizumab (Lucentis) for the treatment of visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV).